Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Postoperative results following FLACS with implantation of FineVision trifocal IOLs in Japanese eyes

Poster Details

First Author: Y.Nishi JAPAN

Co Author(s):    K. Uemura   H. Sakata   S. Fukazawa   M. Shirai   K. Nishi   O. Nishi     

Abstract Details

Purpose:

To investigate the safety and postoperative results following FLACS and implantation of trifocal IOLs in Japanese eyes.

Setting:

Nishi Eye Hospital, Osaka, Japan

Methods:

27 eyes with senile cataract underwent FLACS (Catalys, OptiMedica) and were implanted with trifocal IOLs (Fine Vision, PhysIOL). Then, the postoperative course and complications were investigated and compared with matched eyes with bifocal IOLs (Restore, Alcon).

Results:

In all cases, FLACS were completed without complications. 3 months following implantation of Fine Vision IOLs, uncorrected distant visual acuity, uncorrected near visual acuity, best corrected distant visual acuity, and best corrected near visual acuity were 0.05±0.15, 0.10±0.11, -0.11±0.12, and 0.05±0.10 LogMAR. No patients with Fine Vision IOLs experienced a severe symptom of glare, whereas 18% of the patients with Restore IOLs suffered from it. 42% of the patients with Fine Vision IOLs and 56% with Restore IOLs complained about hallo. The defocus curve showed fine vision IOLs had a tendency to have an improved intermediate vision compared with restore IOLs.

Conclusions:

Fine vision trifocal IOLs showed a good functional result in Japanese eyes. The intermediate vision was especially satisfactory. Less patients complained about postoperative glare or halo. Further follow ups are necessary.

Financial Disclosure:

NONE

Back to Poster listing